Hematology, Transfusion and Cell Therapy最新文献

{"title":"There is no transfer of mitochondria from donor hematopoietic cells to recipient mesenchymal stromal cells after allogeneic hematopoietic stem cells transplantation in humans","authors":"Natalya Sats ,&nbsp;Vadim Surin ,&nbsp;Tatiana Abramova ,&nbsp;Aleksandra Sadovskaya ,&nbsp;Nataliya Petinati ,&nbsp;Nikolay Kapranov ,&nbsp;Ksenia Nikiforova ,&nbsp;Nina Drize ,&nbsp;Luisa Karaseva ,&nbsp;Olga Pokrovskaya ,&nbsp;Larisa Kuzmina ,&nbsp;Elena Parovichnikova","doi":"10.1016/j.htct.2025.103859","DOIUrl":"10.1016/j.htct.2025.103859","url":null,"abstract":"<div><h3>Introduction</h3><div>Multipotent mesenchymal stromal cells are progenitors of the bone marrow stromal microenvironment that support hematopoiesis. Mitochondria, which can be transferred between cells via nanotubes or extracellular vesicles, play a key role in the functions of mesenchymal stromal cells. In a murine model, donor hematopoietic stem and progenitor cells transfer functional mitochondria to bone marrow mesenchymal stromal cells of the recipient. The aim of this study was to find out whether such transfer occurs in humans after allogeneic hematopoietic stem cell transplantation.</div></div><div><h3>Methods</h3><div>This study included nine patients with acute leukemia who received a reduced intensity conditioning regimen. Donor hematopoietic stem and progenitor cells mobilized into peripheral blood were the source of transplanted stem cells. Total DNA was isolated from bone marrow mesenchymal stromal cells of each patient before and after transplantation and their respective donors’ leukocytes. A fragment of mitochondrial DNA including the full-length control region was sequenced. The mitochondrial DNA sequence of each patient’s mesenchymal stromal cells was compared before and after the procedure and with the respective donor leukocytes.</div></div><div><h3>Results</h3><div>Donor mitochondrial DNA was not detected in the mesenchymal stromal cells of any patient after transplantation even as trace amounts. Co-culturing donor leukocytes with intact and irradiated mesenchymal stromal cells <em>in vitro</em> did not lead to detection of donor mitochondrial DNA transfer.</div></div><div><h3>Conclusion</h3><div>The data show that there is no mitochondrial transfer from donor hematopoietic stem and progenitor cells to recipient mesenchymal stromal cells after transplantation. Thus, the results indicate that one cannot count on improved mesenchymal stromal cell metabolism due to mitochondrial transfer. It is necessary to look for other ways to restore the stromal microenvironment.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103859"},"PeriodicalIF":1.8,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144306454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of malaria parasites among blood donors in two hospitals in Enugu metropolis, Nigeria","authors":"Samuel ThankGod Aluh ,&nbsp;Patience Obiageli Ubachukwu ,&nbsp;Kyrian Ikenna Onah ,&nbsp;Gabriel Adebayo Oladepo ,&nbsp;Chidi Ole Ukwen ,&nbsp;Fupsin Rimamkirnde","doi":"10.1016/j.htct.2025.103858","DOIUrl":"10.1016/j.htct.2025.103858","url":null,"abstract":"<div><h3>Introduction</h3><div>Screening of blood donors for malaria parasites as recommended by the World Health Organization (WHO) is currently not included in the protocols and procedures for pre-screening blood donors of many private and public health facilities in Nigeria.</div></div><div><h3>Methods</h3><div>A cross-sectional study was conducted of voluntary, family, and remunerated blood donors in two hospitals in the Enugu metropolis. A well-structured questionnaire was used to collect demographics and blood donation history data. Five milliliters of blood were collected from each blood donor, of which 2 mL were used to screen for malaria parasites.</div></div><div><h3>Results</h3><div>Three hundred and seventy-seven blood donors participated in the study with 148 (39.3 %) being malaria-positive. Most of the blood donors were in the age groups 16–25 and 26–35 years old with prevalences of 40.0 % and 44.1 %, respectively. The prevalence of malaria in both age groups was high compared to the 36–45 years age group (26.7 %). Still, the overall difference in malaria prevalence across the four age groups was not statistically significant (χ² = 5.437; <em>p</em>-value = 0.142). The majority (<em>n</em> = 290; 76.9 %) of the donors were male, while 87 (23.1 %) were female. Although female blood donors had a higher prevalence of malaria (47.1 %) compared to male donors (36.9 %), the difference was not statistically significant (<em>p</em>-value = 0.057).</div></div><div><h3>Conclusion</h3><div>The high prevalence of malaria in the studied area, suggests the need for careful screening of blood samples of blood donors for malaria parasites.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103858"},"PeriodicalIF":1.8,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144314013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"CD36 as a marker of acute myeloid leukemia prognosis: A systematic review","authors":"Marina Chaves Amantéa,&nbsp;Rafaela Pires da Silva,&nbsp;Larissa Ranini Soares,&nbsp;João Lorenzo de Medeiros Pereira,&nbsp;Ana Paula Duarte de Souza","doi":"10.1016/j.htct.2025.103861","DOIUrl":"10.1016/j.htct.2025.103861","url":null,"abstract":"<div><div>CD36 is a glycoprotein associated with resistance to chemotherapy and the recurrence of acute myeloid leukemia. This systematic review aims to evaluate the impact of CD36 on the prognosis of acute myeloid leukemia, a complex heterogeneous malignant hematopoietic disease. The Embase, Scopus, Web of Science, Cochrane Library and SciELO databases were searched until September 2023. Only studies that analyzed CD36 expression in humans were included. Of 905 articles identified from the databases, 600 were screened and nine were included. The Newcastle-Ottawa Scale was used to evaluate the methodological quality of the studies. According to this systematic review, CD36 is associated with different prognostic factors in acute myeloid leukemia, including remission and relapse of the disease, overall survival, and chemoresistance.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103861"},"PeriodicalIF":1.8,"publicationDate":"2025-06-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144290833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of testosterone on blood-clotting markers in transsexual men","authors":"Estella Thaisa Sontag dos Reis,&nbsp;Carla Maria Franco Dias,&nbsp;Carolina Sales Vieira,&nbsp;Mariane Nunes Nadai,&nbsp;Sérgio Henrique Pires Okano,&nbsp;Silvio Antônio Franceschini,&nbsp;Lúcia Alves da Silva Lara","doi":"10.1016/j.htct.2025.103862","DOIUrl":"10.1016/j.htct.2025.103862","url":null,"abstract":"<div><h3>Background</h3><div>The use of testosterone in gender-affirming hormone therapy for trans men is associated with several adverse effects. However, research on the risk of venous thromboembolism in this treatment remains limited and inconclusive. This study aimed to assess the impact of intramuscular testosterone on specific direct and indirect blood-clotting markers in trans men.</div></div><div><h3>Method</h3><div>Treatment of trans men without previous use of testosterone was followed up in a prospective observational study in a trans people healthcare service. Gender-affirming hormone therapy was initiated with intramuscular testosterone cypionate (Depo-Testosterone). The blood-clotting markers prothrombin time, activated partial thromboplastin time, <span>d</span>-dimer, antithrombin, and factors VIII and VII were evaluated before and 12 weeks after starting the medication.</div></div><div><h3>Results</h3><div>Nineteen trans men with a mean age of 23.7 ± 3.7 years were enrolled. After 12 weeks of hormone therapy, significant increases in weight (<em>p</em>-value = 0.002) and body mass index (<em>p</em>-value = 0.007) were observed in patients. Furthermore, there were significant increases of 830 % in serum testosterone (<em>p</em>-value = 0.000), 7 % in hemoglobin (<em>p</em>-value = 0.000) and 10 % in hematocrit (<em>p</em>-value = 0.001). Conversely, a 10 % decrease in high density lipoprotein cholesterol levels (<em>p</em>-value = 0.000), and 15 % decrease in Factor VII (<em>p</em>-value = 0.000) were detected.</div></div><div><h3>Conclusion</h3><div>Intramuscular testosterone in trans men was associated with increases in hematocrit, hemoglobin, and the body mass index, and decreases in high density lipoprotein cholesterol and Factor VII. Nevertheless, these variables remained within normal reference values. Long-term follow-up studies evaluating gender-affirming hormone therapy with testosterone are needed to determine adequate risk management of venous and arterial thromboembolism in this population.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103862"},"PeriodicalIF":1.8,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144279201","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advanced molecular approaches to thalassemia disorder and the selection of molecular-level diagnostic testing in resource-limited settings","authors":"Balaiah Meenakumari,&nbsp;Chandramouleeswari K,&nbsp;Sariga Dhanasekar","doi":"10.1016/j.htct.2025.103860","DOIUrl":"10.1016/j.htct.2025.103860","url":null,"abstract":"<div><div>Beta-thalassemia is a genetic disorder that significantly burdens healthcare systems globally. This inherited blood disorder, categorized into beta-thalassemia and alpha-thalassemia, results in insufficient globin production, leading to anemia and iron overload from frequent transfusions. Severe cases, known as thalassemia major, require regular blood transfusions. Beyond clinical suspicion and biochemical tests, molecular techniques are essential for confirming the diagnosis and guiding treatment. Advanced molecular profiling methods such as Polymerase Chain Reaction (PCR), Multiplex Ligation-dependent Probe Amplification (MLPA), Next-Generation Sequencing (NGS), Third-Generation Sequencing (TGS), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) are effective in detecting mutations. Epigenetic factors also play a crucial role, driving the development of epidrugs for targeted therapy. This review covers various molecular techniques, established gene-editing methods, epigenetic mechanisms, and the impact of artificial intelligence on thalassemia management. It highlights the importance of selecting precise and sensitive molecular tools for detecting thalassemia gene mutations and stresses the need to make these testing methods accessible in resource-limited clinical settings.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103860"},"PeriodicalIF":1.8,"publicationDate":"2025-06-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144288779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-cohort gene expression model enhances prognostic stratification in diffuse large B-cell lymphoma","authors":"Valbert Oliveira Costa Filho ,&nbsp;Felipe Pantoja Mesquita ,&nbsp;Erick Figueiredo Saldanha ,&nbsp;Pedro Robson Costa Passos ,&nbsp;Mariana Macambira Noronha ,&nbsp;Silvia Helena Barem Rabenhorst","doi":"10.1016/j.htct.2025.103847","DOIUrl":"10.1016/j.htct.2025.103847","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103847"},"PeriodicalIF":1.8,"publicationDate":"2025-06-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144263302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy, safety and satisfaction of using emicizumab in hemophilia A patients without factor VIII inhibitors: A systematic review","authors":"Isabela de Oliveira Araujo ,&nbsp;Lucas Fernandes Suassuna ,&nbsp;Isabela Lima dos Santos ,&nbsp;Daniela de Oliveira Werneck Rodrigues","doi":"10.1016/j.htct.2025.103849","DOIUrl":"10.1016/j.htct.2025.103849","url":null,"abstract":"<div><h3>Background</h3><div>Hemophilia A is a genetic disorder characterized by deficiency or dysfunction of the factor VIII clotting protein, leading to serious bleeding disorders. Conventional treatment involves the exogenous administration of factor VIII. However, this therapy faces significant challenges, including the development of inhibitors and the need for frequent intravenous administration. Emicizumab, a recombinant bispecific monoclonal antibody that can be administered subcutaneously, offers a novel therapeutic alternative by mimicking the action of factor VIII.</div></div><div><h3>Methods</h3><div>This systematic review evaluates the efficacy, safety, and patient satisfaction with emicizumab in patients with hemophilia A without inhibitors. A comprehensive literature search was conducted using the MEDLINE, SciELO, and LILACS databases. The included studies were original articles on the use of emicizumab in hemophilia A patients without inhibitors and reviews, short communications, expert comments, and case reports were excluded. Data extraction and analysis were performed using predefined criteria.</div></div><div><h3>Results</h3><div>A total of 471 articles were identified, with 28 meeting the inclusion criteria. Studies demonstrated robust evidence of the efficacy of emicizumab in reducing bleeding episodes, with significant reductions in the Annualized Bleeding Rate and Annualized Joint Bleeding Rate. Safety profiles were favorable, with mainly minor adverse events reported. High patient satisfaction scores highlighted improvements in quality of life and treatment adherence.</div></div><div><h3>Conclusion</h3><div>Emicizumab represents a significant advancement in hemophilia A treatment, offering superior efficacy, safety, and patient satisfaction compared to traditional therapies. Future research should focus on long-term outcomes and specific subpopulations to further validate these findings.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103849"},"PeriodicalIF":1.8,"publicationDate":"2025-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144255078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Closing the gaps: Tackling myeloma inequities in Latin America","authors":"Jorge Contreras","doi":"10.1016/j.htct.2025.103848","DOIUrl":"10.1016/j.htct.2025.103848","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103848"},"PeriodicalIF":1.8,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144212939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The impact of pathogen reduction on ABO isoagglutinin titers in apheresis platelets","authors":"Mikayel Yeghiazaryan ,&nbsp;Yembur Ahmad ,&nbsp;Jessie Singer ,&nbsp;Vaanush Nazaryan ,&nbsp;Craig Fletcher ,&nbsp;Yamac Akgun","doi":"10.1016/j.htct.2025.103840","DOIUrl":"10.1016/j.htct.2025.103840","url":null,"abstract":"<div><h3>Background</h3><div>Platelet transfusions are a cornerstone of modern medical care, used across various clinical contexts. Ensuring the compatibility of blood products, especially regarding ABO isoagglutinins, is critical to minimize adverse reactions. Pathogen reduction technologies have been widely adopted to enhance the safety of blood products, however, the impact of such treatments on ABO isoagglutinin titers in platelet products remains unclear.</div></div><div><h3>Methods</h3><div>This study analyzed 60 apheresis platelet donations, including type O, A, and B donors, using the INTERCEPT® Blood System for pathogen reduction. Samples were collected both from donor whole blood at the time of apheresis (Retention) and from the final pathogen-reduced platelet product after it had passed through the compound adsorption device (Post-CAD). ABO isoagglutinin titers, including both IgM and IgG classes, were measured using solid-phase technology on the NEO Iris platform.</div></div><div><h3>Results</h3><div>This study found a significant reduction in IgM isoagglutinin titers in Post-CAD samples, with 99 % of Retention titers being greater than or equal to their Post-CAD counterparts. IgG titers exhibited more variability, with 9 % of Post-CAD samples displaying higher titers than Retention samples. Statistical analysis confirmed differences between Retention and Post-CAD samples for both IgM and IgG titers, with p-values &lt;0.05 in most comparisons.</div></div><div><h3>Conclusion</h3><div>Pathogen reduction using the INTERCEPT® Blood System effectively reduces ABO isoagglutinin titers in apheresis platelets, potentially lowering the risk of hemolytic transfusion reactions. This reduction is beneficial for safer out-of-group platelet transfusions, especially in vulnerable populations such as pediatric patients. These findings support the continued use of pathogen-reduced platelets in transfusion medicine to enhance both safety and availability of blood products.</div></div>","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103840"},"PeriodicalIF":1.8,"publicationDate":"2025-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144116858","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cutaneous T-cell lymphomas may require an exception to the ABHH consensus regarding empiric vancomycin use in febrile neutropenia","authors":"Yung Gonzaga ,&nbsp;Jose A. Sanches","doi":"10.1016/j.htct.2025.103844","DOIUrl":"10.1016/j.htct.2025.103844","url":null,"abstract":"","PeriodicalId":12958,"journal":{"name":"Hematology, Transfusion and Cell Therapy","volume":"47 3","pages":"Article 103844"},"PeriodicalIF":1.8,"publicationDate":"2025-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144072414","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}